skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Highlights in this white paper include:

Although the standard of care treatment for multiple sclerosis involves immunomodulatory therapy administered via injection, the availability of an oral disease modifying therapy is the latest advance in the treatment of this devastating illness. This paper looks at what the data tells us about the future of new oral drugs in the MS pipeline.

  • Late and mid-stage pipeline immunomodulatory candidates by MS segment and mode of action
  • Types of novel targets being investigated
  • Dissecting the clinical development paths for trends and paradigm shifts
  • Trial focus: is there movement beyond RR-MS?
  • The move to exploration of patients either newly diagnosed or with a potential initial MS symptom